StemCell extends RosetteSep deal with Applied Imaging
This article was originally published in Clinica
Executive Summary
Applied Imaging has renewed its exclusive supply agreement with StemCell Technologies, allowing the San Jose, California company to continue utilising StemCell's RosetteSep reagent technology in conjunction with its Ariol multiparameter cellular analysis system to isolate and analyse circulating tumour cells in cancer patients' blood samples.